Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 251-262

  Cerella, Claudia ^a   Gaigneaux, Anthoula ^a   Dicato, Mario ^a   Diederich, Marc ^b  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Seoul National University   (South Korea)

Author keywords

Cancer; Metabolism; MTOR; Natural compounds

Indexed keywords

ANTINEOPLASTIC AGENT; ARENOBUFAGIN; BUFALIN; CURCUMIN; CYMARIN; DIGITOXIN; DIGOXIN; EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NATURAL PRODUCT; OUABAIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; QUERCETIN; RESVERATROL; SOMALIN; THEAFLAVIN DIGALLATE; UNBS 1450; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; MYC PROTEIN, HUMAN; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

CARCINOGENESIS; CELL METABOLISM; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; METABOLIC REPROGRAMMING; NONHUMAN; NUTRIENT; ONCOGENE; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; GENETICS; METABOLISM; NEOPLASMS; NUCLEAR REPROGRAMMING; PATHOLOGY;

MAMMALIA;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; CURCUMIN; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; QUERCETIN; SIGNAL TRANSDUCTION; STILBENES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920148090     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.008     Document Type: Review

References (113)

1. Cerella C., Radogna F., Dicato M., Diederich M. Natural compounds as regulators of the cancer cell metabolism. Int. J. Cell Biol. 2013, 2013:639401.
2. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
3. Coloff J.L., Macintyre A.N., Nichols A.G., Liu T., Gallo C.A., Plas D.R., Rathmell J.C. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011, 71:5204-5213.
4. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008, 22:1490-1500.
5. Cobbold S.P. The mTOR pathway and integrating immune regulation. Immunology 2013.
6. Marelli-Berg F.M., Fu H., Mauro C. Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. Immunology 2012, 136:363-369.
7. Doherty J.R., Cleveland J.L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 2013, 123:3685-3692.
8. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
9. Liang J., Mills G.B. AMPK: a contextual oncogene or tumor suppressor?. Cancer Res. 2013, 73:2929-2935.
10. Russo G.L., Russo M., Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem. Pharmacol. 2013, 86:339-350.
11. Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 2013, 3.
12. Gottlieb E., Vousden K.H. P53 regulation of metabolic pathways. Cold Spring Harb. Perspect. Biol. 2010, 2:a001040.
13. Yeung S.J., Pan J., Lee M.H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell. Mol. Life Sci. 2008, 65:3981-3999.
14. Howell J.J., Manning B.D. MTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metab. 2011, 22:94-102.
15. Kim S.G., Buel G.R., Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol. Cells 2013, 35:463-473.
16. Orlikova B., Diederich M. Power from the garden: plant compounds as inhibitors of the hallmarks of cancer. Curr. Med. Chem. 2012, 19:2061-2087.
17. Teiten M.H., Eifes S., Dicato M., Diederich M. Curcumin - the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2010, 2:128-162.
18. Cerella C., Sobolewski C., Dicato M., Diederich M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem. Pharmacol. 2010, 80:1801-1815.
19. Seidel C., Schnekenburger M., Dicato M., Diederich M. Histone deacetylase modulators provided by Mother Nature. Genes Nutr. 2012, 7:357-367.
20. Orlikova B., Legrand N., Panning J., Dicato M., Diederich M. Anti-inflammatory and anticancer drugs from nature. Cancer Treat Res. 2014, 159:123-143.
21. C. Cerella, M. Kelkel, E. Viry, M. Dicato, C. Jacob, M. Diederich, Naturally occurring organic sulfur compounds: an example of a multitasking class of phytochemicals in anti-cancer research, in: I. Rasooli (Ed.), Anti-Cancer Research, Phytochemicals - Bioactivities and Impact on Health, InTech, Rijeka, Croatia, 2011, pp. 1-40.
22. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
23. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., Vander Heiden M.G., MacKeigan J.P., Finan P.M., Clish C.B., Murphy L.O., Manning B.D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
24. Sun Q., Chen X., Ma J., Peng H., Wang F., Zha X., Wang Y., Jing Y., Yang H., Chen R., Chang L., Zhang Y., Goto J., Onda H., Chen T., Wang M.R., Lu Y., You H., Kwiatkowski D., Zhang H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 2011, 108:4129-4134.
25. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
26. Wang B.T., Ducker G.S., Barczak A.J., Barbeau R., Erle D.J., Shokat K.M. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc. Natl. Acad. Sci. USA 2011, 108:15201-15206.
27. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc .Natl. Acad. Sci. USA 2008, 105:17414-17419.
28. Simons A., Orcutt K., Madsen J., Scarbrough P., Spitz D. The role of Akt pathway signaling in glucose metabolism and metabolic oxidative stress. Oxidative Stress in Cancer Biology and Therapy 2012, 21-46. Humana Press. R. Spitz, K. Dornfeld, K. Krishnan, D. Gius (Eds.).
29. Mills J.R., Hippo Y., Robert F., Chen S.M., Malina A., Lin C.J., Trojahn U., Wendel H.G., Charest A., Bronson R.T., Kogan S.C., Nadon R., Housman D.E., Lowe S.W., Pelletier J. MTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. USA 2008, 105:10853-10858.
30. Faubert B., Boily G., Izreig S., Griss T., Samborska B., Dong Z., Dupuy F., Chambers C., Fuerth B.J., Viollet B., Mamer O.A., Avizonis D., DeBerardinis R.J., Siegel P.M., Jones R.G. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013, 17:113-124.
31. Ollila S., Makela T.P. The tumor suppressor kinase LKB1: lessons from mouse models. J. Mol. Cell Biol. 2011, 3:330-340.
32. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 2008, 105:18782-18787.
33. Pourdehnad M., Truitt M.L., Siddiqi I.N., Ducker G.S., Shokat K.M., Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl. Acad. Sci. USA 2013, 110:11988-11993.
34. Masui K., Tanaka K., Akhavan D., Babic I., Gini B., Matsutani T., Iwanami A., Liu F., Villa G.R., Gu Y., Campos C., Zhu S., Yang H., Yong W.H., Cloughesy T.F., Mellinghoff I.K., Cavenee W.K., Shaw R.J., Mischel P.S. mTOR Complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013, 18:726-739.
35. Schwartzenberg-Bar-Yoseph F., Armoni M., Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64:2627-2633.
36. Vousden K.H., Ryan K.M. P53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
37. Kawauchi K., Araki K., Tobiume K., Tanaka N. P53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 2008, 10:611-618.
38. Hasty P., Sharp Z.D., Curiel T.J., Campisi J. MTORC1 and p53: clash of the gods?. Cell Cycle 2013, 12:20-25.
39. Feng Z., Hu W., de Stanchina E., Teresky A.K., Jin S., Lowe S., Levine A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67:3043-3053.
40. Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 2013, 104:275-281.
41. Budanov A.V., Karin M. P53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134:451-460.
42. Hay N. P53 strikes mTORC1 by employing sestrins. Cell Metab. 2008, 8:184-185.
43. Loayza-Puch F., Drost J., Rooijers K., Lopes R., Elkon R., Agami R. p53 Induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol. 2013, 14:R32.
44. Sawadogo W.R., Schumacher M., Teiten M.H., Cerella C., Dicato M., Diederich M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011. Molecules 2013, 18:3641-3673.
45. Cerella C., Michiels C., Dashwood R.H., Surh Y.J., Diederich M. Metabolism and cancer: old and new players. Int. J. Cell Biol. 2013, 2013:293201.
46. Teiten M.H., Eifes S., Reuter S., Duvoix A., Dicato M., Diederich M. Gene expression profiling related to anti-inflammatory properties of curcumin in K562 leukemia cells. Ann. N.Y. Acad. Sci. 2009, 1171:391-398.
47. Teiten M.H., Gaascht F., Cronauer M., Henry E., Dicato M., Diederich M. Anti-proliferative potential of curcumin in androgen-dependent prostate cancer cells occurs through modulation of the Wingless signaling pathway. Int. J. Oncol. 2011, 38:603-611.
48. Teiten M.H., Gaascht F., Eifes S., Dicato M., Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010, 5:61-74.
49. Teiten M.H., Dicato M., Diederich M. Curcumin as a regulator of epigenetic events. Mol. Nutr. Food Res. 2013, 57:1619-1629.
50. Duvoix A., Blasius R., Delhalle S., Schnekenburger M., Morceau F., Henry E., Dicato M., Diederich M. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005, 223:181-190.
51. Kelkel M., Jacob C., Dicato M., Diederich M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules 2010, 15:7035-7074.
52. Reuter S., Eifes S., Dicato M., Aggarwal B.B., Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 2008, 76:1340-1351.
53. Beevers C.S., Zhou H., Huang S. Hitting the golden TORget: curcumin's effects on mTOR signaling. Anticancer Agents Med. Chem. 2013, 13:988-994.
54. Sun Z.J., Chen G., Zhang W., Hu X., Liu Y., Zhou Q., Zhu L.X., Zhao Y.F. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-kappaB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IkappaB kinase complex signaling axis in adenoid cystic carcinoma. Mol. Pharmacol. 2011, 79:106-118.
55. Lim H.W., Lim H.Y., Wong K.P. Uncoupling of oxidative phosphorylation by curcumin: implication of its cellular mechanism of action. Biochem. Biophys. Res. Commun. 2009, 389:187-192.
56. Yu S., Shen G., Khor T.O., Kim J.H., Kong A.N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther. 2008, 7:2609-2620.
57. Bae M.K., Kim S.H., Jeong J.W., Lee Y.M., Kim H.S., Kim S.R., Yun I., Bae S.K., Kim K.W. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol. Rep. 2006, 15:1557-1562.
58. Lin J.K. Molecular targets of curcumin. Adv. Exp. Med. Biol. 2007, 595:227-243.
59. Li M., Zhang Z., Hill D.L., Wang H., Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007, 67:1988-1996.
60. Pallauf K., Rimbach G. Autophagy, polyphenols and healthy ageing. Ageing Res. Rev. 2013, 12:237-252.
61. Vaughan R.A., Garcia-Smith R., Dorsey J., Griffith J.K., Bisoffi M., Trujillo K.A. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int. J. Cancer 2013, 133:2504-2510.
62. Beevers C.S., Chen L., Liu L., Luo Y., Webster N.J., Huang S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res. 2009, 69:1000-1008.
63. Hwang J.T., Park I.J., Shin J.I., Lee Y.K., Lee S.K., Baik H.W., Ha J., Genistein Park O.J. E.G.C.G. and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 2005, 338:694-699.
64. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
65. Ahn J., Lee H., Kim S., Park J., Ha T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem. Biophys. Res. Commun. 2008, 373:545-549.
66. Lin C.L., Huang H.C., Lin J.K. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J. Lip. Res. 2007, 48:2334-2343.
67. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29:698-706.
68. Fogarty S., Hardie D.G. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 2010, 1804:581-591.
69. Juncker T., Cerella C., Teiten M.H., Morceau F., Schumacher M., Ghelfi J., Gaascht F., Schnekenburger M., Henry E., Dicato M., Diederich M. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem. Pharmacol. 2011, 81:13-23.
70. Slingerland M., Cerella C., Guchelaar H.J., Diederich M., Gelderblom H. Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. Invest. New Drugs 2013, 31:1087-1094.
71. Cerella C., Dicato M., Diederich M. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion 2013, 13:225-234.
72. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med. Hypotheses 1999, 53:543-548.
73. Mijatovic T., Mathieu V., Gaussin J.F., De Neve N., Ribaucour F., Van Quaquebeke E., Dumont P., Darro F., Kiss R. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 2006, 8:402-412.
74. Newman R.A., Kondo Y., Yokoyama T., Dixon S., Cartwright C., Chan D., Johansen M., Yang P. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr. Cancer Ther. 2007, 6:354-364.
75. Xie C.M., Chan W.Y., Yu S., Zhao J., Cheng C.H. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radical. Biol. Med. 2011, 51:1365-1375.
76. Wang Y., Qiu Q., Shen J.J., Li D.D., Jiang X.J., Si S.Y., Shao R.G., Wang Z. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. Int. J. Biochem. Cell Biol. 2012, 44:1813-1824.
77. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., Semenza G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 2008, 105:19579-19586.
78. Gayed B.A., O'Malley K.J., Pilch J., Wang Z. Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors. Clin. Transl. Sci. 2012, 5:39-42.
79. Masuda Y., Kawazoe N., Nakajo S., Yoshida T., Kuroiwa Y., Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk. Res. 1995, 19:549-556.
80. Mijatovic T., De Neve N., Gailly P., Mathieu V., Haibe-Kains B., Bontempi G., Lapeira J., Decaestecker C., Facchini V., Kiss R. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol. Cancer Ther. 2008, 7:1285-1296.
81. Chanvorachote P., Pongrakhananon V. Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis. Am. J. Physiol. Cell Physiol. 2013, 304:C263-C272.
82. Zhang D.M., Liu J.S., Deng L.J., Chen M.F., Yiu A., Cao H.H., Tian H.Y., Fung K.P., Kurihara H., Pan J.X., Ye W.C. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis 2013, 34:1331-1342.
83. Perne A., Muellner M.K., Steinrueck M., Craig-Mueller N., Mayerhofer J., Schwarzinger I., Sloane M., Uras I.Z., Hoermann G., Nijman S.M., Mayerhofer M. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 2009, 4:e8292.
84. Didiot M.C., Hewett J., Varin T., Freuler F., Selinger D., Nick H., Reinhardt J., Buckler A., Myer V., Schuffenhauer A., Guy C.T., Parker C.N. Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation. J. Biomol. Screen 2013, 18:407-419.
85. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266.
86. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y., Phase I. Clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
87. Lao C.D., Ruffin M.T.t., Normolle D., Heath D.D., Murray S.I., Bailey J.M., Boggs M.E., Crowell J., Rock C.L., Brenner D.E. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 2006, 6:10.
88. Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013, 15:195-218.
89. Wang S., Su R., Nie S., Sun M., Zhang J., Wu D., Moustaid-Moussa N. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem. 2013.
90. Kakkar V., Singh S., Singla D., Kaur I.P. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol. Nutr. Food Res. 2011, 55:495-503.
91. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64:353-356.
92. Russo M., Spagnuolo C., Tedesco I., Bilotto S., Russo G.L. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol. 2012, 83:6-15.
93. Lam T.K., Rotunno M., Lubin J.H., Wacholder S., Consonni D., Pesatori A.C., Bertazzi P.A., Chanock S.J., Burdette L., Goldstein A.M., Tucker M.A., Caporaso N.E., Subar A.F., Landi M.T. Dietary quercetin, quercetin-gene interaction, metabolic gene expression in lung tissue and lung cancer risk. Carcinogenesis 2010, 31:634-642.
94. Lamson D.W., Brignall M.S. Antioxidants and cancer, Part 3: Quercetin. Altern. Med. Rev. 2000, 5:196-208.
95. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., Baker J., Kerr D.J. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 1996, 2:659-668.
96. Kim M.K., Park K.S., Yeo W.S., Choo H., Chong Y. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg. Med. Chem. 2009, 17:1164-1171.
97. Howells L.M., Britton R.G., Mazzoletti M., Greaves P., Broggini M., Brown K., Steward W.P., Gescher A.J., Sale S. Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3',4',5'-trimethoxyflavonol, a quercetin analogue. Cancer Prev. Res. (Phila) 2010, 3:929-939.
98. Makino T., Shimizu R., Kanemaru M., Suzuki Y., Moriwaki M., Mizukami H. Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol. Pharm. Bull. 2009, 32:2034-2040.
99. Yuan Z.P., Chen L.J., Fan L.Y., Tang M.H., Yang G.L., Yang H.S., Du X.B., Wang G.Q., Yao W.X., Zhao Q.M., Ye B., Wang R., Diao P., Zhang W., Wu H.B., Zhao X., Wei Y.Q. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res. 2006, 12:3193-3199.
100. Egert S., Boesch-Saadatmandi C., Wolffram S., Rimbach G., Muller M.J. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J. Nutr. 2010, 140:278-284.
101. Egert S., Bosy-Westphal A., Seiberl J., Kurbitz C., Settler U., Plachta-Danielzik S., Wagner A.E., Frank J., Schrezenmeir J., Rimbach G., Wolffram S., Muller M.J. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 2009, 102:1065-1074.
102. Boots A.W., Drent M., de Boer V.C., Bast A., Haenen G.R. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin. Nutr. 2011, 30:506-512.
103. Conquer J.A., Maiani G., Azzini E., Raguzzini A., Holub B.J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 1998, 128:593-597.
104. Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol. 2008, 585:325-337.
105. Ishisaka A., Ichikawa S., Sakakibara H., Piskula M.K., Nakamura T., Kato Y., Ito M., Miyamoto K., Tsuji A., Kawai Y., Terao J. Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radical. Biol. Med. 2011, 51:1329-1336.
106. Tome-Carneiro J., Larrosa M., Gonzalez-Sarrias A., Tomas-Barberan F.A., Garcia-Conesa M.T., Espin J.C. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19:6064-6093.
107. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila) 2009, 2:409-418.
108. Soleas G.J., Yan J., Goldberg D.M. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J. Chromatogr. B Biomed. Sci. Appl. 2001, 757:161-172.
109. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36:79-87.
110. Siedlinski M., Boer J.M., Smit H.A., Postma D.S., Boezen H.M. Dietary factors and lung function in the general population: wine and resveratrol intake. Eur. Respir. J. 2012, 39:385-391.
111. Mijatovic T., Dufrasne F., Kiss R. Cardiotonic steroids-mediated targeting of the Na(+)/K(+)-ATPase to combat chemoresistant cancers. Curr. Med. Chem. 2012, 19:627-646.
112. Juncker T., Schumacher M., Dicato M., Diederich M. UNBS1450 from Calotropis procera as a regulator of signaling pathways involved in proliferation and cell death. Biochem. Pharmacol. 2009, 78:1-10.
113. Sweeny L., Hartman Y.E., Zinn K.R., Prudent J.R., Marshall D.J., Shekhani M.S., Rosenthal E.L. A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma. Oral Oncol. 2013, 49:991-997.